Predicting the effects of drugs before human clinical trials is at the heart of drug screening
and discovery processes. The cost of drug discovery is steadily increasing owing to the …

Tremendous progress has been achieved in the field of tissue engineering in the past
decade. Several major challenges laid down 10 years ago, have been studied, including …

Organ-on-a-chip systems are miniaturized microfluidic 3D human tissue and organ models
designed to recapitulate the important biological and physiological parameters of their in …

Engineering cardiac tissues and organ models remains a great challenge due to the
hierarchical structure of the native myocardium. The need of integrating blood vessels brings …

The complex interaction of cells with biomaterials (ie, materiobiology) plays an increasingly
pivotal role in the development of novel implants, biomedical devices, and tissue …

Significant advances in biomaterials, stem cell biology, and microscale technologies have
enabled the fabrication of biologically relevant tissues and organs. Such tissues and organs …

Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Vascularization of 3D models represents a major challenge of tissue engineering and a key
prerequisite for their clinical and industrial application. The use of prevascularized models …

Current in vitro antitumor drug screening strategies insufficiently mimic biological systems.
They tend to lack true perfusion and draining microcirculation systems, which may post …

Organ-on-chip devices have provided the pharmaceutical and tissue engineering worlds
much hope since they arrived and began to grow in sophistication. However, limitations for …